Merck Patent Gesellschaft Mit Beschraenkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19792923267external-prioritypatent/DE2923267A1/en
Priority claimed from DE19792923268external-prioritypatent/DE2923268A1/en
Priority claimed from DE19792923266external-prioritypatent/DE2923266A1/en
Priority claimed from DE19803004304external-prioritypatent/DE3004304A1/en
Application filed by Merck Patent Gesellschaft Mit Beschraenkter HaftungfiledCriticalMerck Patent Gesellschaft Mit Beschraenkter Haftung
Priority claimed from EP80102486Aexternal-prioritypatent/EP0020959B1/en
Application grantedgrantedCritical
Publication of ATE3980T1publicationCriticalpatent/ATE3980T1/en
Vitamin=B2 intermediate N-D-ribityl-3,4-xylidine prodn. - from ribose in form of epimer mixt. obtd. by epimerisation of D-arabinose with molybdenum cpds.